CHRM2 and cardiovascular disorder: Although the specific subtype of CHRM that QAX028 targets is not publicly available, the antagonists of CHRM1, CHRM2, and CHRM3 have all been investigated in CVRM-related indications based on documentation from the Open Targets Platform.2 Finally, osteopontin (SPP1 or OPN) is a potential target for cardiovascular diseases based on observational data (17).